GlassScriptPhysician profile
Robert Noecker
NPI 1588638217
$632,350.25
in general payments reported to CMS, 2019-2025
32 companies · $101K in 2025
The $101K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $27K · 2021: $47K · 2022: $115K · 2023: $141K · 2024: $147K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $181K · Consulting Fee: $157K · Travel and Lodging: $34K · Food and Beverage: $16K · Honoraria: $1,500 · Grant: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $180,600.00 |
| Consulting Fee | $156,677.82 |
| Travel and Lodging | $33,757.84 |
| Food and Beverage | $16,381.24 |
| Honoraria | $1,500.00 |
| Grant | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $264,796.05 | 2022-2025 | |
| Alcon Vision LLC | $108,218.25 | 2020-2025 | Hydrus Microstent, Voyager Dslt, Eysuvis |
| Allergan, INC. | $48,321.80 | 2020-2022 | |
| Glaukos Corporation | $42,065.74 | 2022-2025 | Idose, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Idosetr |
| Novartis Pharmaceuticals Corporation | $36,039.16 | 2019-2023 | |
| Iridex Corporation | $26,250.00 | 2022-2023 | |
| Microsurgical Technology, INC. | $22,685.28 | 2022-2025 | |
| Sight Sciences, INC. | $19,719.19 | 2019-2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17,684.47 | 2019-2020 | |
| Beaver-Visitec International, INC. | $16,578.10 | 2022-2023 | |
| Kala Pharmaceuticals, INC. | $10,682.89 | 2019-2022 | |
| Nova Eye, INC. | $7,797.16 | 2023-2025 | |
| Ivantis, INC | $4,365.51 | 2019-2021 | |
| New World Medical,INC. | $2,605.52 | 2019 | |
| Thea Pharma INC. | $2,004.87 | 2023-2025 | Iyuzeh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $582.45 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $339.28 | 2022-2025 | Vyzulta, Prolensa, Miebo |
| Oyster Point Pharma, INC. | $274.05 | 2022-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $235.46 | 2020-2024 | Tecnis Iol, Tecnis Simplicity |
| Rayner Intraocular Lenses Limited | $189.72 | 2024 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Ocular Therapeutix, INC. | $158.38 | 2020-2025 | Dextenza |
| Aerie Pharmaceuticals, INC. | $152.83 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $148.60 | 2024-2025 | Xdemvy |
| Rxsight INC | $143.96 | 2024-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $136.80 | 2022-2025 | |
| Dompe US, INC. | $43.10 | 2024-2025 | Oxervate |
| Astellas Pharma US INC | $34.94 | 2023 | |
| Harrow Eye, LLC | $31.75 | 2025 | Vevye |
| Horizon Therapeutics Plc | $20.73 | 2023 | Tepezza |
| Omeros Corporation | $17.79 | 2019 | |
| Shire North American Group INC | $15.01 | 2019 | |
| Alcon Research LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Noecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.